Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study is being conducted in patients with major depression. The study aims to 1) investigate the combined effects of selective serotonin reuptake inhibitor (SSRI) and bupropion compared to SSRI alone on the improvements of depressive symptoms, fatigue, hypersomnia, and neurocognitive functions, 2) observe structural/functional/chemical changes using magnetic resonance imaging (MRI), 3) and examine a relationship between the improvements of depressive symptoms, fatigue, and hypersomnia and the neural changes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Depression Following Multiple Brain Tests

NCT00296777

Major Depression Dysthymia

COMPLETED PHASE4

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

NCT02191397

Depressive Disorder, Major

COMPLETED PHASE3

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101

Major Depression

COMPLETED PHASE4

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169

Depression

TERMINATED PHASE4

Lethargic Depression Study

NCT00064467

Epilepsy Major Depressive Disorder (MDD)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Escitalopram + Bupropion

Group Type EXPERIMENTAL

Bupropion, Escitalopram

Intervention Type DRUG

Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg

Escitalopram

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupropion, Escitalopram

Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg

Intervention Type DRUG

Escitalopram

Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged between 20 and 65
* Diagnosis of major depressive disorder (MDD) as assessed by the Structured Clinical Interview for DSM-IV (SCID-IV)
* Individuals who provided written consent for participation.

Exclusion Criteria

* Presence of any major physical or neurological illness (e.g., head trauma, epilepsy, seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease, narrow-angle glaucoma, drug hypersensitivity, etc.)
* Diagnosis of any Axis I disorder other than MDD or presence of symptoms requiring hospitalization
* Intelligence quotient (IQ) below 80
* Contraindications to magnetic resonance imaging (e.g., pacemaker implantation, claustrophobia, etc.)
* Unstable medical illness or other abnormalities observed at the screening or laboratory tests
* Women who are pregnant, breastfeeding, or planning pregnancy
* Allergy or tolerance to the clinical trial medication
* Presence of any physical illness that contraindicates the clinical trial medication (e.g., epilepsy, history of uncontrollable narrow-angle glaucoma)
* Use of psychoactive medications that may affect brain imaging findings

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No